Angiotensin (1-7) vs BPC-157

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

A heptapeptide formed from angiotensin II via ACE2 cleavage, or from angiotensin I via neprilysin. Acts as the endogenous counter-regulatory axis to angiotensin II — producing vasodilation, anti-fibrotic, and metabolic benefits via the Mas receptor.

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is commonly researched for its role in soft tissue repair, particularly in tendons, ligaments, and muscle following injury or high training loads. Early research suggests it may also support gut integrity and systemic healing.